Your SlideShare is downloading. ×
05 Mesotelioma pleural maligno y timoma
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

05 Mesotelioma pleural maligno y timoma

128
views

Published on

Autor/a Dra. Pilar Lianes …

Autor/a Dra. Pilar Lianes
V Jornada de Revisión del Congreso Mundial de Cáncer de Pulmón.
ARCO MEDITERRANEO. Valencia 8-Nov-2013

Published in: Health & Medicine

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
128
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Diagnostics Problems
  • 2. Thymoma and Thymic Carcinoma: Differences Stages at presentation Paraneoplastic syndromes in thymic carcinoma rarely IHC differences: EGFR more common in thymoma C-kit more common in thymic carcinoma Poorer prognosis of thymic carcinoma
  • 3. Summary Thymic Tumors Thymoma and Thymic Carcinoma are unique entities Both are sensitive to broad range of chemotherapeutic agents Anthracycline regimens associated with higher response rates in Thymoma In Stage III Disease, radiation improves PFS but not OS We need to better identify the “targets” for targeted therapy Always consider multidisciplinary aproach
  • 4. The present study indicated that appropriately selected patients who underwent radical P/D had lower perioperative morbidity and mortality with similar, if not superior, long-term survival compared to EPP.
  • 5. QUÉ HEMOS APRENDIDO EN EL MUNDIAL 2013 de Mesoteliomas Que existe un grupo de trabajo internacional muy activo interesado en su diagnóstico y tratamiento (IMIG) Que las sesiones han sido muy ricas en contenido y discusión Que la prevención epidemiológica aún es posible Que tenemos esperanza en drogas prometedoras Que los pacientes se merecen nuestro esfuerzo multidisciplinar